Orphatec Pharmaceuticals GmbH

If you mentioned “orphan drugs” to a pharma audience even three years ago, just a handful of drug manufacturers would likely have come to mind: the pioneer Genzyme Corp. , naturally, along with com

Alexion Pharmaceuticals Inc. ’s strategy of label expansion for high-priced terminal complement inhibitor Soliris (eculizumab), combined with targeted acquisitions to add other candidates for ultra

IN VITRO DIAGNOSTICS Alliances AEterna Zentaris Inc. Roche Ventana Medical Systems Inc. In one of two companion diagnostics deals it signed on the same day, Roche Diagnostics Corp. ’s Ventana Med

Alexion Pharmaceuticals Inc. announced on Dec. 28 that it has agreed to pay up to $1.08 billion for privately held Enobia Pharma Inc. in a transaction that includes both upfront and milestone pa